北京時間12月1日消息,美國股票評級服務公司TheStreet Ratings已將安捷倫的股票評級從“持有”上調至“買入”。
評級報告要點包括:
安捷倫收入增長低于行業平均水平25.6%,去年同期至今,公司收入微增5.1%。數據顯示公司EPS(每股收益)下降幅度較大,但收入增長速度沒有觸及公司底線。
公司目前的權益負債率0.52,負債率較低且低于行業平均水平,說明公司對債務水平的管控非常成功。公司速動比率達2.43,顯示公司有非常強的短期償債能力。
與去年同時期相比,當前雖然公司盈利水平較差,但是公司股票交易非常活躍。我們知道,即使是最好的股票在市場全面下跌時股價也會下跌,但在其他情況下,不管過去股價是否已經上漲,這類公司的股價都具有良好的升值潛力。
安捷倫公司盈利水平已經連續兩年大幅下降,但他們成功經受住了持續兩年的考驗,我們預期公司盈利水平下降的趨勢將發生反轉。公司每股收益由前年的2.11美元下降至1.47美元,但是今年市場預測每股收益將由1.47美元提高至1.73美元。
您可以在這里看到評級報告全文:
http://secure2.thestreet.com/cap/prm.do?OID=023499&ticker=A
Agilent Technologies (A) Upgraded From Hold to Buy
Must Read: Warren Buffett's 25 Favorite StocksSTOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.Highlights from the analysis by TheStreet Ratings Team goes as follows:
A's revenue growth trails the industry average of 25.6%. Since the same quarter one year prior, revenues slightly increased by 5.1%. This growth in revenue does not appear to have trickled down to the company's bottom line, displayed by a decline in earnings per share.
The current debt-to-equity ratio, 0.52, is low and is below the industry average, implying that there has been successful management of debt levels. To add to this, A has a quick ratio of 2.43, which demonstrates the ability of the company to cover short-term liquidity needs.
Compared to where it was a year ago today, the stock is now trading at a higher level, regardless of the company's weak earnings results. Turning our attention to the future direction of the stock, it goes without saying that even the best stocks can fall in an overall down market. However, in any other environment, this stock still has good upside potential despite the fact that it has already risen in the past year.
AGILENT TECHNOLOGIES INC has experienced a steep decline in earnings per share in the most recent quarter in comparison to its performance from the same quarter a year ago. The company has suffered a declining pattern of earnings per share over the past two years. However, we anticipate this trend to reverse over the coming year. During the past fiscal year, AGILENT TECHNOLOGIES INC reported lower earnings of $1.47 versus $2.11 in the prior year. This year, the market expects an improvement in earnings ($1.73 versus $1.47).
新實驗室已通過美國CLIA實驗室資質認證,可確保從早期檢測開發與測試到伴隨診斷全面商業化的無縫銜接。2024年9月11日,北京——安捷倫科技公司(紐約證交所:A)近日宣布其位于加利福尼亞州卡平特里亞的......
......
今天要講到的代謝組學妙手來自何方? 來自我們優秀的用戶——邁理奧(Meliomics)。邁理奧的快速崛起,源自于他們對代謝組學領域的深刻理解和持續創新,而安捷倫出色的儀器和解決方案也為其提供......
今年3月,發表于《自然-通訊》(NatureCommunications)雜志上的《Anexposomeatlasofserumrevealstheriskofchronicdiseasesinthe......
......
安捷倫提供的全套法規認證服務,包括基于USP<1058>分析儀器確認(AIQ)的儀器和軟件確認(IQOQ、OQ和RQ),是數據可靠性的基礎。我們提供了自動化的電子法規認證解決方案,旨在支持......
......
多肽藥物是介于小分子藥物和大分子藥物之間的一種特殊藥物,其結構特征、合成方法和劑型都有自身的特殊性。多肽藥物合成過程中可能生成差向肽、缺失肽和錯結肽等雜質,很多雜質與目標產物的結構、化學性質非常相近,......
安捷倫最新推出的8850氣相色譜儀,出色的柱溫箱內部熱動力學設計,輔以優化的加熱部件,賦予8850GC優異的快速升、降溫特性,同時秉承安捷倫一如既往的穩定可靠和技術領先;體積只有傳統GC物理空間一半,......
脂質納米顆粒(LNPs)是當下生物醫藥領域突破性的工具,特別是在mRNA疫苗和治療的遞送中顯示出了其卓越的潛能。隨著COVID-19mRNA疫苗的成功應用,LNPs的研究和開發獲得了前所未有的關注。這......